Despite the magnitude of the medical problem which prostate cancer constitutes, a basic understanding of the molecular events responsible for the initiation and progression of this disease remains elusive. The goal of the proposed research is to identify, localize and characterize consistent alterations in the prostate cancer cell genome. This information is prerequisite for the long term goal of this project which is to identify and clone the genes which, as a result of genetic alteration, are responsible for prostate carcinogenesis. To this end, a systematic approach utilizing molecular and cell biology techniques will be employed to analyze molecular genetic aspects of human prostate cancer. Specifically, three different project areas will be pursued. 1) We will identify and evaluate candidate prostate tumor suppressor genes located at chromosome 8p22. At this location we have identified a one megabase (or smaller) region that has a high probability of containing a novel prostate tumor suppressor gene based upon previous deletion mapping studies. 2) To provide the basis for identification of additional genes involved in prostate cancer genomic hybridization (CGH) to be frequently deleted in advanced prostate cancer, i.e. the long arms of chromosomes 2,5,6 and 13. Similarly, regions shown by CGH to be consistently amplified in advanced prostate cancer (i.e. the short arm of chromosome 7 and the long arms of chromosomes 8,9 and 17) will be delineated by amplicon mapping. Tumors to be analyzed will include localized and metastatic cancers from treated and untreated men as well as PIN lesions and cancers from men with a strong family history of prostate cancer. 3) An assessment of DNA methylation- associated gene suppression will be undertaken to determine the potential role of this non-mutational mechanism of tumor suppression will be undertaken to determine the potential role of this non-mutational mechanism of tumor suppressor gene inactivation in prostate cancer progression. This project will complement other projects in our SPORE program, in particular, the linkage analysis and other studies involving characterization of genetic alterations in prostate cancer. It is anticipated that this multifaceted approach will generate new prognostic markers as well as identify new therapeutic targets in prostate cancer, resulting in an increased ability to effectively diagnose and treat this extremely common malignancy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058236-06
Application #
6102867
Study Section
Project Start
1998-07-28
Project End
1999-05-31
Budget Start
Budget End
Support Year
6
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Jiang, Wen; Ulmert, David; Simons, Brian W et al. (2018) The impact of age on radium-223 distribution and an evaluation of molecular imaging surrogates. Nucl Med Biol 62-63:1-8
Tsang, Sabrina H; Peisch, Samuel F; Rowan, Brendan et al. (2018) Association between Trichomonas vaginalis and prostate cancer mortality. Int J Cancer :
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151
Kaur, Harsimar B; Guedes, Liana B; Lu, Jiayun et al. (2018) Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer. Mod Pathol 31:1539-1552
Zhu, Yezi; Sharp, Adam; Anderson, Courtney M et al. (2018) Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. Eur Urol 73:727-735
Teply, Benjamin A; Wang, Hao; Luber, Brandon et al. (2018) Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol 19:76-86
Zennami, Kenji; Choi, Su Mi; Liao, Ross et al. (2018) PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance. Mol Cancer Res :
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225

Showing the most recent 10 out of 750 publications